Company news

Genfleet Therapeutics (Shanghai), Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2026

November 4, 2026

VOLUNTARY ANNOUNCEMENT Multiple Innovative Combination Therapies of Oral Pan RAS Inhibitor GFH276 Recently Granted with Clinical Trial Approvals for First-line and Late-line Clinical Studies Addressing Major Tumor Indications in China or Abroad

November 3, 2026

Next Day Disclosure Return

November 3, 2026

Next Day Disclosure Return

November 2, 2026

Next Day Disclosure Return

October 30, 2026

Next Day Disclosure Return

October 29, 2026

Next Day Disclosure Return

October 28, 2026

Next Day Disclosure Return

October 26, 2026

VOLUNTARY ANNOUNCEMENT Initial Clinical Readout of GFH276 (an Oral Molecular-glue Pan RAS Inhibitor) Presented as Late-breaking Abstract (LBA) at 2026 ESMO Annual Meeting, Demonstrating Promising Clinical Potential and Favorable Safety in Pretreated RAS-mutant Solid Tumors

October 25, 2026

VOLUNTARY ANNOUNCEMENT GFH375/VS-7375 (Oral KRAS G12D Inhibitor) Achieves Positive Progress across Multiple Clinical Studies in China and Abroad, with Promising Efficacy in Various RAS-mutant Solid Tumors

October 14, 2026

Next Day Disclosure Return

October 13, 2026

Next Day Disclosure Return

October 8, 2026

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026

October 5, 2026

Next Day Disclosure Return

September 28, 2026

List of directors and their roles and functions

September 24, 2026

Resignation of non-executive director

September 24, 2026

VOLUNTARY ANNOUNCEMENT Disclosure Arrangements for Clinical Data from Studies of GFH375 and GFH276

September 22, 2026

Announcement pursuant to rule 13.10 of the listing rules

September 21, 2026

VOLUNTARY ANNOUNCEMENT Announcement on the Progress of Share Repurchase

September 20, 2026

2026 Interim Report

September 16, 2026

VOLUNTARY ANNOUNCEMENT Favorable Phase II Efficacy Data of GFH375 (Oral KRAS G12D Inhibitor) Monotherapy in Pretreated NSCLC Presented in Oral Session at 2026 World Conference on Lung Cancer (WCLC)

September 14, 2026

Voluntary announcement proposed share repurchase on the market

June 28, 2026

Decks